27-Jun-2019NewGeneral

Dr James Garner provides comprehensive GDC-0084 update to Morgans

Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on Kazia’s ongoing trials for its lead candidate, GDC-0084.

 

The interview covers: 

 

  • Kazia’s phase II study in newly diagnosed glioblastoma (GBM) patients which determined a higher maximum tolerated dose than Genentech’s phase I study in patients with recurrent disease.
  • How recruiting for the phase I study in Diffuse Intrinsic Pontine Glioma (DIPG) with St Jude Children's Research Hospital is progressing well, with preliminary data anticipated in 2H2019.
  • The ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.
  • Kazia’s valuation compared to other US companies developing PI3K inhibitors.

 

Listen to the podcast here: